High-dose biotin in progressive multiple sclerosis: A prospective study of 178 patients in routine clinical practice.
Mult Scler
; 26(14): 1898-1906, 2020 12.
Article
em En
| MEDLINE
| ID: mdl-31845825
ABSTRACT
BACKGROUND:
A recent controlled trial suggested that high-dose biotin supplementation reverses disability progression in patients with progressive multiple sclerosis.OBJECTIVE:
To analyze the impact of high-dose biotin in routine clinical practice on disability progression at 12 months.METHODS:
Progressive multiple sclerosis patients who started high-dose biotin at Nantes or Rennes Hospital between 3 June 2015 and 15 September 2017 were included in this prospective study. Disability outcome measures, patient-reported outcome measures, relapses, magnetic resonance imaging (MRI) data, and adverse events were collected at baseline, 6, and 12 months.RESULTS:
A total of 178 patients were included. At baseline, patients were 52.0 ± 9.4 years old, mean Expanded Disability Status Scale (EDSS) score was 6.1 ± 1.3, mean disease duration was 16.9 ± 9.5 years. At 12 months, 3.8% of the patients had an improved EDSS score. Regarding the other disability scales, scores either remained stable or increased significantly. In total, 47.4% of the patients described stability, 27.6% felt an improvement, and 25% described a worsening. Four patients (2.2%) had a relapse. Of the 74 patients (41.6%) who underwent an MRI, 20 (27.0%) had new T2 lesions, 8 (10.8%) had gadolinium-enhancing lesions. Twenty-five (14%) reported adverse event.CONCLUSION:
In this study, high-dose biotin did not seem to be associated with a clear improvement in disability.Palavras-chave
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Esclerose Múltipla Crônica Progressiva
/
Esclerose Múltipla Recidivante-Remitente
/
Esclerose Múltipla
Tipo de estudo:
Observational_studies
/
Risk_factors_studies
Limite:
Adult
/
Humans
/
Middle aged
Idioma:
En
Revista:
Mult Scler
Assunto da revista:
NEUROLOGIA
Ano de publicação:
2020
Tipo de documento:
Article
País de afiliação:
França